Clinical Trial Update: Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating bevacizumab for malignant pleural effusions in patients with non-squamous non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Effusion
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Malignant Pleural Effusion | Phase 2 | Status: UNKNOWN